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Cardioplegic solutions: Unproved herbal approach
versus tested scientific study
To the Editor:
The two criteria for cardiac surgical success are a techni-
cally adequate procedure and safe myocardial protection.
Experienced surgeons can readily introduce satisfactory tech-
nical changes that visibly work. For example, a coronary
anastomosis can be made with interrupted or running sutures,
by passing a needle either from the outside to inside, or inside
to outside, and either one surgeon doing all, or two surgeons,
each doing half, to maintain an ongoing forehand direct
suturing method. The barometer is that the anastomosis is
hemostatic, is patent, and remains open at follow-up exami-
nation. This end point is clear and documentable.
These specific limitations with cardioplegia may not be
clear in the operating room without this knowledge. For
example, an untested solution may produce a minor decrease
in protection, resulting in raised left ventricular end-diastolic
pressure (or left atrial pressure increases from 8 mm Hg to 16
mm Hg) with normal cardiac output in normal hearts. This
depression of the Starling function curve is not clear from
baseline resting measurements. However, cardiac output may
not increase sufficiently during anemia or fever. Of course,
these changes can occur also with tested solutions with any
form of myocardial protection, especially in damaged hearts.
Recognition of changes by a solution alone allows more
proper selection of crystalloid or blood cardioplegic con-
stituents.
The surgeon is not qualified to make arbitrary changes in
solutions to meet a whim. Suspicion of a useful change is
only a reason for pharmacologic testing. This was stated
clearly by Claude Bernard: “Clinical anecdotes should be the
seeds of subsequent investigative studies, and not the basis of
future decision making.”
The calcium concentration (Ca++) is lowered in the cardio-
plegic solution and reperfusate, because intracellular Ca++
accumulation follows ischemic and reperfusion injury.
However, Ca++ is not lowered too severely (<50 m m) to avoid
sarcolemmal damage that is caused by the calcium paradox.
This deleterious change was seen at the outset of clinical
cardioplegia with the Melrose solution in 1955. Careful
experimental testing (as described above) was not done. We
now know that Ca++ was lowered severely when citrate-phos-
phatedextrose (CPD) solution (which chelates calcium) was
added in high concentrations. Cardioplegia was initially
abandoned and then subsequently restored when
Bretschneider in 1964 and Gay and Ebert in 1971 imple-
mented experimental studies and showed clear benefits.
Today, our current blood cardioplegic solution uses safer
potassium and citrate components than were used in the orig-
inal Melrose solution. The quantity of blood/cardioplegia
mixture is recorded, and Ca++ is lowered to 0.5 to 0.6 m mol/L
with a 4:1 mixture and more severely, to 0.2 to 0.3 m mol/L, in
solutions for energy-depleted hearts or those with acute
myocardial infarction.
Similar testing with crystalloid Bretschneider solution or St
Thomas’ Hospital solution exposed the potential advantages
and disadvantages of these approaches. Consequently, the lit-
erature contains comparisons that allow surgeons to make
more knowledgeable selections of a desired blood or crystal-
loid solution.
I will relate specific issues with blood cardioplegia to show
that inaccurate choices can be problematic. Several years ago,
in children, we saw immediately after aortic unclamping,
transient atrioventricular dissociation or ventricular fibrilla-
tion. Normal rhythm was readily restored by pacing or defib-
rillation. The spontaneous beating empty state seen in adults
was not routine. We found that our hemodilution primes
diluted Ca++ to 0.6 to 0.8 m m in the blood component of our
cardioplegic solution. This iatrogenic hypocalcemia devel-
oped after extracorporeal circulation was begun and before
the cardioplegic mixture was made. Clearly a further lower-
ing of Ca++ occurred with any cardioplegic solution contain-
ing a fixed CPD concentration.
The lowering depended on the pump prime, with its known
content of Ringer’s lactate or electrolyte solution (Plasma-
Lyte). A supplemental plasma component will lower Ca++
further. We worked out the formulation of the amount of cal-
cium to be added to the crystalloid or crystalloid/plasma
pump prime to restore Ca++ to normal limits. These transient
arrhythmias were avoided by restoring normal Ca++ in the
pump prime.1
A more serious problem occurred at another institution.
The surgeon did not dilute our 4:1 cardioplegic solution, but
administered the entire cardioplegic component (containing
high potassium and CPD) directly into the heart. A problem
similar to that with the Melrose solution occurred, and a
patient died. I2 reported this hazard in a letter partially titled,
“Cardioplegic Solutions Are Not Equal.”
St Thomas’ Hospital solution (ie, a crystalloid solution)
was described in that report to show that this solution can be
delivered directly into the heart without blood. Our blood car-
dioplegic components were also presented to show that the
crystalloid components of blood cardioplegia would differ
depending on the ratio of 8:1, 4:1, 1:1, or other values.
Clearly, a reverse problem occurs by mixing crystalloid St
Thomas’ Hospital solution with blood, unless the electrolyte
concentrations are increased.
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St Thomas’ Hospital solution contains magnesium, 16
mEq/L, and normal calcium at 1.2 m L/L. As with blood car-
dioplegia, hypocalcemia in St Thomas’ Hospital solutions
was reported by Baker, Olinger, and Baker3 to be an impor-
tant cardioplegic element in hypoxic immature hearts. To pro-
duce hypocalcemia with St Thomas’ Hospital solution, there
was consideration of adding CPD, since CPD is used routine-
ly in blood cardioplegic solutions. The crystalloid component
of St Thomas’ Hospital solution is different from the blood
cardioplegic crystalloid aliquot sample, so that new testing
was needed.
The role of a careful investigator, making an experimental
evaluation before changing the clinical solution, became
clear. A laboratory study was done by Frank Rosenfeldt of
Melbourne, Australia (personal communication, 1999).
Adding CPD to St Thomas’ Hospital solution (containing 16
m L/L calcium) caused marked depression (ie, >50%) in left
ventricular function in normal ventricles. Conversely, lower-
ing calcium to 0.25 m mol/L, as seen in the blood cardioplegic
study, was useful. This dilemma of adding CPD to St
Thomas’ Hospital solution was clear, and Dr Rosenfeldt and
colleagues avoided making this change clinically. Conversely,
failure to do this evaluation may provide an intraoperative
counterpart of decreased function (as we described earlier).
Consequently, in more damaged hearts, severe complications
such as arrhythmia or mortality might occur because of the
lack of proper experimental evaluation before clinical intro-
duction.
Several years ago, I asked a commercial pharmaceutical
company to produce our cardioplegic solution because of a
clinical problem encountered in a western state. Before that,
our group made glutamate/aspartate solution in the hospital at
the University of California at Los Angeles (UCLA) in a
pharmacy that had good manufacturing practices. Many
groups wanted to change to add amino acids, so we published
and distributed the method of UCLA formulation to any hos-
pital that made such requests.
A western hospital that used our formulations found them
successful in more than 1000 cases. Evidently, the hospital
pharmacy changed, and a new pharmacist observed
Escherichia coli in 2 of 30 bottles that were made. Several
bottles on either side of the contaminated ones were discard-
ed. Random testing of 2 other bottles showed that no other
contamination occurred. However, the pharmacist did not
check or discard all bottles because of “isolated” contamina-
tion. Unfortunately, 2 patients died and 6 others had severe
infections. Cardiac function was normal. These morbidity
and mortality changes relate to the manufacturing practice in
a specific pharmacy. This deleterious consequence led the
Food and Drug Administration to shut down hospital phar-
macies making amino acid solutions where good manufactur-
ing practices were not present.
Hospital pharmacies had to prove to the Food and Drug
Administration that they were capable of making solutions
with proper environments. For this reason, we went to a phar-
maceutical company, McGaw, with a subsidiary CAPS
(Central Admixture Pharmacy Services) to ensure that our
solution was made safely, with reliable preparation, and that
others could obtain this in a predictable way.
We4 recently reported the benefit of L-arginine as an addi-
tive to our cardioplegic solution. This additive was selected
because of our interest in cardioplegia to protect the endothe-
lium as well as the myocardium. Our experiment reports
show that myocardial function was excellent with both solu-
tions, but L-arginine provided endothelial protection. A surgi-
cal colleague, reading this, began to add L-arginine to his car-
dioplegic solution. His source was a company that provided
solutions for experimental laboratories. These are sterile
solutions, but this laboratory does not make solutions for
patients.
The use of an untested solution, although producing no
acute cardiovascular effects, caused renal failure in 6 patients.
Subsequent analysis showed that the L-arginine solution con-
tained arsenic and other nephrotoxic agents. The kidney, not
the heart, was affected adversely. This, of course, was not
seen with our clinical protocol, where 20 patients received
the L-arginine cardioplegic solution without effect. We asked
the pharmaceutical company making our glutamate/aspartate
clinical solution to add the L-arginine additive.
The same surgical colleague avoided these renal changes
by administering the L-arginine solution additive from this
same pharmaceutical source. The composite glutamate/aspar-
tate L-arginine solution has now been administered in more
than 500 cases, without renal damage.
Similar problems with either improper additives or bacter-
ial contamination can occur when perfusionists, with no phar-
macologic or electrolyte physiologic background, must con-
struct a cardioplegic solution. This may be especially
problematic if done under emergency circumstances.
These vignettes are recorded to call attention to the adverse
effects from changing cardioplegic solutions for well-inten-
tioned surgical considerations, but without clinical testing.
All cardioplegic solutions can be supplemented to augment
their benefit, but careful testing is needed before their clinical
application. Surgeons making changes on a conceptual basis
alone can produce dilemmas they did not desire. This phar-
macologic limitation differs from the advantages of solid sur-
gical judgment to make decisions, as in the coronary anasto-
mosis described previously.
Fortunately, many tested crystalloid or blood cardioplegic
solutions are made and used worldwide. Clearly, pharmaceu-
tical firms, and some hospitals with good manufacturing
practices, can safely produce these solutions. This may avoid
complications related directly to a cardioplegic solution used
for myocardial protection.
I was surprised to learn from CAPS that although there is
wide use of the glutamate/aspartate supplementation to blood
cardioplegic solutions, several institutions made changes
from the originally described concentrations. Of course, these
changes may be safe, but only testing will prove that the com-
position of an otherwise untested solution did not cause a
clinical problem. Detrimental cardiac or other organ changes
may be difficult to defend if no background data are available
regarding how the solution was evaluated before its clinical
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use. The analogy of a comparison between “unproven herbal
approach versus tested scientific study” must be considered.
Gerald D. Buckberg, MD
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Emerging new concepts of myocardial laser revas-
cularization
To the Editor:
Zenati, Cohen, and Griffith1 express support for the devel-
opment of centers in which different revascularization proce-
dures would be performed in the same patient by teams com-
posed of interventional cardiologists and cardiovascular
surgeons. Will myocardial laser revascularization (MLR),
either percutaneous or surgical, find its place in such team-
work when its original idea of perfusion of the left ventricle
from its cavity is no longer valid?2
In the meantime, a new concept trying to explain why MLR
has been beneficial to some patients has emerged: angiogen-
esis as a nonspecific response of the myocardium to injury.
All the same, this concept is usually considered unfit to serve
as a vehicle for MLR because this procedure leads only rarely
to the improvement of objective parameters such as cardiac
perfusion and function, exercise capacity, and survival.2
Before MLR is abandoned, we must be sure that it (1) has
been used correctly and (2) was applied to suitable patients. I
am afraid this has not always been the case.
Angiogenesis fulfills its purpose only if a source of oxy-
genated blood is available. This condition provided, angio-
genesis diminishes ischemia solely if it leads to the develop-
ment of collateral vessels linking the ischemic with the
well-perfused myocardium.3 In agreement with these con-
cepts, cardiomyocyte death induced by MLR would lead to
inflammatory angiogenesis and wound healing reaction.
Newly formed capillaries would connect blood vessels of the
lased ischemic region with blood vessels of neighboring well-
perfused areas. The angiogenesis would not subside after the
healing of laser channels because friction between noncom-
pliant laser channel scars and the contractile surrounding
myocardium would induce continuous injury and inflamma-
tion.4 New capillaries would not regress because of a pressure
gradient between the well-perfused myocardium and the
ischemic region.3 The remodeling of capillary-sized collater-
als into arterioles and arteries would complete the revascular-
ization, that is, the collateralization of the ischemic region.
Contrary to the above hypotheses, MLR has been used
mostly in patients with diffuse multivessel end-stage coro-
nary artery disease with contraindications to percutaneous
transluminal coronary angioplasty and coronary artery
bypass grafting. It is obvious that angiogenesis is of no use if
the whole ventricle is ischemic. On the contrary, the use of
MLR in combination with coronary artery bypass grafting
and/or coronary angioplasty (as it would be practiced in inte-
grated revascularization centers) is an excellent idea. The
conventional techniques would provide the source of well-
oxygenated blood wherever possible, and MLR would facili-
tate the development of collateral vessels in the areas inac-
cessible for traditional revascularization. It is worthy of note
that Mirhoseini, Shelgikar, and Cayton,5 the inventors of
MLR, used this method in combination with coronary artery
bypass grafting when they started to apply it to patients. This
undoubtedly explains their success. Recently, Trehan and col-
leagues6 used MLR in combination with minimally invasive
coronary artery bypass grafting and claimed excellent results.
All this suggests that MLR, if used in conjunction with other
methods of revascularization, will find its place in the thera-
peutic armamentarium used against ischemic heart disease.
Jiri T. Beranek
4101 S Wappel Dr
Columbia, MO 65203
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Reply to the Editor:
We enjoyed reading Beranek’s comments and discussion of
myocardial laser revascularization (MLR). Our concept of
integrated coronary revascularization is in constant evolution,
as new techniques become available both to the cardiac sur-
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